Therapeutic agents targeting v-erb-b2
avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2, best known as HER2/Neu) are an essential component of the standard treatment of HER2 + breast carcinoma patients. 1 However, the mechanisms by which HER2/Neu-targeting interventions mediate the antitumor response have not yet been completely revealed. Although endogenous adaptive immune responses targeting HER2/Neu were described in breast cancer patients over 15 y ago, 2 the role of adaptive immunity in HER2/Neu-targeting therapy has only recently become appreciated. This new understanding originates, in large part, to preclinical studies demonstrating that Rag1−/− and CD8-deficient mice bearing HER2/Neu + tumors are significantly impaired in their ability to respond to anti-HER2/Neu therapy. 3, 4 Given the profound therapeutic implications of these findings, determining the mechanisms through which HER2/Neu-targeting agents elicit or boost endogenous antitumor immune responses is of tremendous importance. To this end, we have recently demonstrated that CD4 + T cells as well as the interaction between CD40 and its ligand (CD40L) within the tumor microenvironment play an essential role in the therapeutic activity of HER2/Neu-targeting agents. 5 In particular, we transplanted a HER2/ Neu + tumor model in immunocompetent mice to further examine the requirement for adaptive immunity in the therapeutic activity of HER2/Neu-targeting antibodies. Although depleting CD4 + regulatory T cells (Tregs) has been shown to prevent the growth of HER2/Neu + tumors, 6 we observed that the depletion of CD4 + T cells significantly inhibited the efficacy of anti-HER2/Neu antibodies. These results suggested that after the administration of HER2/Neu-targeting antibodies, the positive role of CD4 + effector T cells in antitumor immune responses is more prominent than that of CD4 + Tregs. Anti-HER2/Neu therapy was also less efficient when CD4 + T cell-depleting antibodies were administered after the cessation of HER2/Neu-targeting antibodies. Thus, the requirement for CD4 + T cells was not limited to early phase immune responses, which are traditionally associated with helper T-cell activity, nor was the effect consistent with alleviation of immunosuppression by CD4 + Tregs. Rather, our data suggested that CD4 + T cells might exert relatively direct antitumor effects (Fig. 1) .
To address this issue, we examined the functional capacity of CD8 + T cells in the absence of CD4 + T cells via interferon Preclinical studies have established that CD8 + T cells are necessary for efficient immunotherapeutic regimens targeting v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (erBB2, best known as her2/Neu). recently, we extended upon these findings by demonstrating that anti-her2/Neu therapy also requires CD4 + T cells and CD40/ CD40L signaling within the tumor microenvironment. Our results add to mounting evidence demonstrating that adaptive immunity is crucial to the efficacy of conventional and targeted anticancer chemotherapeutics.
The contribution of both CD8
+ and CD4 + T cells to the therapeutic efficacy of HER2/Neu-targeting agents supports current efforts to develop anticancer vaccines for treating HER2/Neu + tumors. Multiple vaccines targeting HER2/Neu are currently in clinical trials, but one issue arising from these studies is the need to induce both CD4 + and CD8 + T cells. 7 Therefore, combining vaccination with HER2/Neu-targeting agents may be a promising strategy to enhance the endogenous immune response against HER2/Neu + neoplasms. Currently, multiple Phase I and Phase II studies are being conducted based on this approach. Administering immune checkpoint blockers following anti-HER2/Neu therapy may represent an alternative approach to improve antitumor immune responses. Indeed, preclinical data suggest that antibodies blocking programmed cell death 1 (PDCD1, best known as PD-1) enhance the efficacy of HER2/Neu-targeting therapies. 4 In addition to systemic CD4 + T cell depletion, we also examined the effects of intratumoral CD4 + T cell depletion. This approach demonstrated that CD4 + T cells within the tumor microenvironment are essential, and suggested that cell-to-cell interactions may be required for the fullblown therapeutic activity of HER2/ Neu-targeting therapies. One important factor for CD4 + T cell effector function, and ultimately CD8 + T cell responses, is the interaction between CD40 and CD40L. 8 Using intratumoral injections of specific antibodies, we observed that blocking CD40/CD40L interactions within the tumor microenvironment significantly reduced the efficacy of anti-HER2/Neu therapy. Moreover, the blockade of CD40/CD40L interactions within neoplastic lesions reduced the functional capacity of T cells in situ, but not in the periphery, suggesting a predominant role for CD40/CD40L interactions within the tumor microenvironment. Future studies based on the adoptive transfer of CD40L-deficient T cells or the provision of CD40 agonists in the absence of CD4 + T cells will clarify the essential role of CD40/CD40L interactions in this setting.
It should be noted that blocking CD40L intratumorally resulted in a significant, yet partial, phenotype. This implies that multiple interactions within the tumor microenvironment contribute to the antitumor response generated by anti-HER2/ Neu therapy. Understanding these interactions is essential, especially in light of the fact that initially antineoplastic T cell effector functions may eventually elicit immunosuppressive mechanisms through The essential role of adaptive immunity in the efficacy of HER2/Neutargeting interventions suggests that this immunotherapeutic approach is not as passive as previously categorized. 7 Our findings also suggest that anti-HER2/ Neu approaches may be favorably combined with other immunotherapies. Overall, our study extends previous findings suggesting that the adaptive immune system is necessary for the efficacy of anti-HER2/Neu therapy. In addition, it adds to accumulating evidence suggesting that adaptive immunity is crucial for the efficacy of conventional and targeted antineoplastic agents, and supports the ongoing effort toward the development of novel immunochemotherapeutic regimens.
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